Redeye: Strax - Low Market Expectations

Report this content

Redeye lowers its short-term expectations on Strax due to the corona-crisis. Our long-term view of the case remains optimistic, with an experienced team managing the business and a vast distribution network providing a competitive edge. On the back of a solid Q4'19-report and a share price decline of 50% during March, we identify an attractive opportunity for the long-term investor.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.